Business Wire

GA-FINEOS

14.7.2020 15:17:03 CEST | Business Wire | Press release

Share
FINEOS Welcomes Allison Morgan as New Senior Sales Executive for North America

FINEOS Corporation (ASX:FCL ), the leading core platform for life, accident and health insurance globally, today announces the appointment of Allison Morgan as Senior Sales Executive to the FINEOS North American team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200714005639/en/

Allison brings nearly 25 years of proven experience as an accomplished absence and disability sales leader and consultant with powerful relationship building, negotiation, communication and presentation skills. She has a proven track record and demonstrated ability to obtain, grow and retain a customer base to support organizational objectives.

In her new role at FINEOS, Allison will be responsible for developing new business clients for FINEOS Claims , FINEOS Absence and FINEOS AdminSuite . Alison’s expertise in absence management is especially important as Integrated Disability and Absence management (IDAM ) becomes a major product offering for insurance carriers serving the Employee Benefits space. She will work closely with brokers, consultants, and complementary product vendors within the Employee Benefits market.

FINEOS AdminSuite is a modern integrated core processing system that consists of absence, claims, payments, billing, policy, and provider administration – all of which are configurable to operate independently or optimally as a full core suite as part of the SaaS delivered FINEOS Platform , powered by AWS.

Prior to joining FINEOS, Allison worked for eight years at Reed Group, a Guardian company, where she was responsible for new business development of absence management software and outsourcing opportunities, focusing on the design of short and long term disability and absence programs for companies with 5,000 employees and above. Previously, she held senior positions in large insurance companies and brokers including MetLife and Aon Hewitt.

“We are delighted to welcome Allison to the FINEOS team and look forward to working closely with her to continue to help insurance carriers in North America realize the benefits of partnering with FINEOS,” said Michael Kelly , CEO, FINEOS. “In addition to having to transform their business to a fully digital model that delivers excellent customer experience, insurers need to provide risk-based products integrated with comprehensive service offerings that include non-traditional products and services, like IDAM. Our 100% commitment to the Employee Benefits market requires experienced people with a strong understanding of the market today and where it is going in the future. Allison brings that next level of focus on IDAM within the Employee Benefits market for FINEOS. We couldn’t be more pleased to have her on board.”

“I am thrilled to join FINEOS, who is known throughout the insurance industry as the leading provider of core technology solutions. As insurers evaluate their current technology, they are recognizing a critical need to effectively and efficiently meet the growing needs of their customers, both employees and employers, who continue to demand a best-in-class product, service and claims experience enabled by modern technology,” said Allison Morgan, senior sales executive for North America. “Additionally, as entitlement laws continue to pass, insurers need state-of-the-art technology solutions to maintain compliance with various federal, state and local laws. FINEOS brings together all of those considerations to create efficient and robust technology solutions enabling the insurer or Third-Party Administrator to focus on better serving their customers and partnering with FINEOS to achieve their growth objectives.”

About FINEOS Corporation

FINEOS is a leading provider of core systems for life, accident and health insurers globally with 7 of the 10 largest group life and health carriers in the US as well as 6 of the largest life insurers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive insurers in North America, Europe, and Asia Pacific.

The FINEOS Platform provides clients full end to end core insurance administration and includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.

For more information, visit www.FINEOS.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/fineos

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release

CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release

A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye